Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
The Skin Center Dermatology Group
Summary
Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥18 years. * Clinical and/or histopathologic diagnosis of LPP. * Presence of scalp pruritus. * Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1. * Ability and willingness to provide written informed consent and comply with study procedures. * Willingness to undergo optional scalp biopsy for research purposes. Exclusion Criteria: * Other forms of alopecia that may interfere with study assessments. * Any systemic disease associated with hair loss. * Inflammatory or infectious scalp disease that may interfere with the study.…
Interventions
- DrugNemolizumab
subcutaneous injection
Location
- The Skin Center Dermatology GroupNew City, New York